menu search

Galectin therapeutics to share five scientific presentations at the liver meeting™ 2023, hosted by the aasld

Pharmacokinetics and safety of belapectin in patients with hepatic insufficiency Lack of impact of belapectin on cardiac repolarization (QT interval) ...

November 3, 2023, 12:00 pm

Atossa therapeutics' (z)-endoxifen being evaluated as alternative treatment for ductal carcinoma in situ

Atossa Therapeutics Inc (NASDAQ:ATOS)'s selective estrogen receptor modulator (Z)-endoxifen is being evaluated in a Phase 2 study aimed at preventing ...

October 30, 2023, 3:11 pm

It's time to get on my soapbox, educate and tell the technical story of the usdchf

The USDCHF this week progressed through a series of steps technically, that played like a symphonic orchestra. In this video, I get on my soapbox, loo...

October 27, 2023, 1:41 pm

Opko health to present new clinical data on rayaldee (er calcifediol) at kidney week 2023

MIAMI, Oct. 25, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) will present late-breaking clinical data on RAYALDEE® extended-release calci...

October 25, 2023, 4:25 pm

Potential of arvinas’ protac® ar degraders reinforced by 11.1 months rpfs with bavdegalutamide and updated positive interim data from second generation arv-766 in mcrpc

– Data presented at the European Society for Medical Oncology from the Phase 1/2 trial with bavdegalutamide showed 11.1 months radiographic ...

October 22, 2023, 11:00 am

: merck’s keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer

Merck & Co. MRK said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-containing che...

October 20, 2023, 12:13 pm

Merck's keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer

Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-contai...

October 20, 2023, 8:13 am

Biogen to present new data at the clinical trials on alzheimer's disease (ctad) 2023 meeting

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer's disease portfolio at the upc...

October 19, 2023, 7:30 am

Davita says news of ozempic's potential in treating kidney disease may have only limited impact for patients, says further studies will be needed

Dialysis company DaVita Inc. DVA, -16.86% issued a statement on Thursday in response to the news Wednesday from Novo Nordisk that its Ozempic treatmen...

October 12, 2023, 8:43 am

Australia's csl tanks as novo nordisk's kidney trial success stokes competition concerns

Shares of biotechnology firm CSL fell to a four-year low on Thursday, after rival Novo Nordisk's Ozempic drug showed early signs of success in delayin...

October 12, 2023, 1:54 am

Zyversa therapeutics announces peer-reviewed publication in nature reviews nephrology substantiating var 200’s rationale for mediating transport of cholesterol and lipids out of kidney cells to attenu

This review paper summarizes numerous research studies that address the role of kidney cholesterol and lipid accumulation in the development and ...

October 11, 2023, 11:05 am

Zyversa therapeutics announces peer-reviewed publication in nature reviews nephrology substantiating var 200’s rationale for mediating transport of cholesterol and lipids out of kidney cells to attenu

This review paper summarizes numerous research studies that address the role of kidney cholesterol and lipid accumulation in the development and ...

October 11, 2023, 11:05 am

Ultralife corporation: on the up, but wait for a better entry point

Ultralife manufactures portable power solutions and communication systems for a range of industries. The company has put in place certain initiatives ...

October 10, 2023, 4:03 pm

Gri bio announces publication of comprehensive invariant nkt (inkt) cell review in frontiers in immunology demonstrating a key role of type 1 inkt cells in modulating various fibrotic conditions

In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in th...

October 5, 2023, 12:45 pm

Novartis (nvs) lutathera meets primary goal in phase iii study

Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful prog...

September 25, 2023, 1:32 pm

Axi launches axi select – a funding program offering up to $1m for traders

Axi Select is a new all-inclusive, capital allocation programme, is specifically designed to empower traders and facilitate their ...

September 25, 2023, 4:00 am

Zyversa therapeutics announces research published in the journal of clinical investigation reinforcing ic 100’s rationale for inhibiting asc specks to attenuate spread of inflammation into surrounding

Patients with chronic kidney disease (“CKD”) exhibit chronic systemic inflammation characterized by increased circulating levels of IL-1β, IL-6, ...

September 22, 2023, 10:35 am

Astrazeneca breast cancer drug gives drugs giant £5bn boost

AstraZeneca PLC (LSE:AZN)'s share price surged by 2.6%, adding nearly £5 billion to the company's market value, following the announcement of encoura...

September 22, 2023, 7:33 am

Astrazeneca signals strong results from breast cancer drug trial

AstraZeneca PLC (LSE:AZN) has hailed strong results from an ongoing trial on the effects of drug datopotamab deruxtecan in breast cancer patients. Acc...

September 22, 2023, 2:54 am

Fda accepts merck (mrk) snda for welireg in renal cell carcinoma

The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically me...

September 20, 2023, 12:02 pm


Search within

Pages Search Results: